Showing 1781-1790 of 5693 results for "".
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th
- FDA Selects Dompé for National Priority Voucher Program to Accelerate Development of Novel Intranasal Therapyhttps://modernod.com/news/fda-selects-dompe-for-national-priority-voucher-program-to-accelerate-development-of-novel-intranasal-therapy/2484190/Dompé announced its selection by the FDA to participate in the Commissioner’s National Priority Voucher (CNPV) program. Through this designation, Dompé has been awarded a voucher granting a signific
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development-1/2481623/Novel findings from researchers at the Brigham and Women's Hospital and Harvard Medical School, in collaboration with the Health Campus Göttingen in Germany, contradict previous notions about sugar's role in the onset of diabetic cataracts, according to a University Medical Center G&
- Peeq Waiva Multipurpose Eyelid Cleansing Device Now Availablehttps://modernod.com/news/peeq-waiva-multipurpose-eyelid-cleansing-device-now-available/2481525/Peeq Pro has announced the launch of the Peeq Waiva, an at-home cleansing device designed for daily use to gently and effectively clean eyelids and the skin around the eyes. When used consistently as part of a patient's at-home eye cleansing routine, the device is designed
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Glasgow Eye Department Now Using Ocular Simulation Training Through DRV Systemhttps://modernod.com/news/glasgow-eye-department-now-using-ocular-simulation-training-through-drv-system/2480954/Simulation exposure is now an essential component of the Royal College of Ophthalmologists’ Ophthalmic Specialist Training curriculum prior to real-life surgery, according to a news release from Vision Engineering Group, a maker of ergonomic stereo optical and digital instruments. &nbs
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- Nova Eye Medical Reports Canaloplasty Data Demonstrating Sustained Reduction in IOP with iTrackhttps://modernod.com/news/nova-eye-medical-reports-canaloplasty-data-demonstrating-sustained-reduction-in-iop-with-itrack/2480849/Nova Eye Medical reported the recent publication of three investigator-led, retrospective case series which evaluated the long-term effectiveness of canaloplasty in patients with open-angle glaucoma (OAG) over 36- and 48-month periods, and in post-keratoplasty patients. Performed b
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategyhttps://modernod.com/news/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy/2480411/Kiora Pharmaceuticals is the new name of EyeGate Pharmaceuticals. The new brand reflects the company’s aim to not only treat common eye conditions, but to develop a small molecule therapy for retinitis pigmentosa. Kiora will trade on the Nasdaq
- Oertli’s CataRhex 3 Device Now Equipped With Speep Pump Innovationhttps://modernod.com/news/oertlis-catarhex-3-device-now-equipped-with-speep-pump-innovation/2479420/Oertli Instrumente has expanded the CataRhex 3 to include the pump innovation, “SPEEP,” which is designed to provide more efficiency and precision in cataract surgery due to precise control of flow and vacuum. The CataRhex 3 is Oertli’s compact and portable surgical platf